You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

What's New in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

  • Authors: Peter Hillmen, MB, ChB; Alexander Röth, MD; Jeff Szer, MBBS
  • CPD Released: 2/11/2022
  • Valid for credit through: 2/11/2023
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of hematology specialist outside the United States.

The goal of this activity is to stay up to date with the latest developments on emerging therapies for paroxysmal nocturnal hemoglobinuria (PNH) and understand where these therapies will fit in the treatment algorithm.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Current unmet needs in the management of patients with PNH
    • Rationale for the development of novel therapies for PNH
    • Latest clinical outcomes with current and emerging therapies for patients with PNH


Disclosures

WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.


Faculty

  • Peter Hillmen, MB, ChB

    Professor of Experimental Hematology
    University of Leeds
    Leeds, United Kingdom

    Disclosures

    Disclosure: Peter Hillmen, MB, ChB, has the following relevant financial relationships:
    Advisor or consultant for: Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Janssen; Swedish Orphan Biovitrum
    Speaker or a member of a speakers bureau for: Abbvie; Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; AstraZeneca Pharmaceuticals; BeiGene; Janssen; Roche; Swedish Orphan Biovitrum
    Grants for clinical research from: AbbVie, Inc.; Apellis Pharmaceuticals; Gilead Sciences, Inc.; Janssen; Pharmacyclics, Inc.; Roche
    Other: Independent contractor for: AbbVie, Inc.; Alexion Pharmaceuticals; Apellis Pharmaceuticals; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Janssen; Pharmacyclics, Inc.; Roche; Swedish Orphan Biovitrum

  • Alexander Röth, MD

    Professor
    Department of Hematology and Stem Cell Transplantation
    West German Cancer Center
    University Hospital Essen
    University of Duisburg-Essen
    Essen, Germany

    Disclosures

    Disclosure: Alexander Röth, MD, has the following relevant financial relationships:
    Advisor or consultant for: Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; BioCryst; Bioverativ; Kira Pharmaceuticals; Novartis; Roche; Sanofi; Sobi
    Speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Apellis Pharmaceuticals; Bioverativ; Novartis; Roche; Sanofi; Sobi
    Grants for clinical research from: Roche

  • Jeff Szer, MBBS

    Professor
    Department of Medicine
    Royal Melbourne Hospital
    Faculty of Medicine, Health and Dentistry
    The University of Melbourne
    Clinical Haematology
    Peter MacCallum Cancer Centre and Royal Melbourne Hospital
    Melbourne, Victoria, Australia

    Disclosures

    Disclosure: Jeff Szer, MBBS, has the following relevant financial relationships:
    Advisor or consultant for: Alexion Pharmaceuticals, Inc.; Novartis; Prevail; Swedish Orphan Biovitrum; Takeda
    Speaker or a member of a speakers bureau for: Alexion Pharmaceuticals, Inc.; Novartis; Pfizer, Inc.; Swedish Orphan Biovitrum; Takeda
    Other: Independent contractor for: Alexion Pharmaceuticals, Inc.; Novartis; Prevail; Swedish Orphan Biovitrum; Takeda

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Sanneke Koekkoek has disclosed no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Disclosure: Chii Shyang Fong, PhD, has disclosed no relevant financial relationships.

Compliance Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

What's New in the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Authors: Peter Hillmen, MB, ChB; Alexander Röth, MD; Jeff Szer, MBBSFaculty and Disclosures

CPD Released: 2/11/2022

Valid for credit through: 2/11/2023

processing....